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Abstract
Purpose of Review Cardiovascular disease (CVD) is the leading cause of death in women worldwide. Preeclampsia (PE) is an
important and acknowledged female-specific risk factor. Women with a history of PE have an elevated risk to develop hyper-
tension in the decade following their index pregnancy. In this paper, we aim to provide recent insights in the future risk of
preeclampsia and describe how prevention strategies can be optimized.
Recent Findings The development of premature hypertension is caused by multiple factors such as genetics and a persistent
enhanced inflammatory state after PE. Systemic inflammation accelerates endothelial dysfunction and promotes the process of
atherosclerosis. In formerly preeclamptic women, signs of subclinical atherosclerosis are present at young age. Timely cardio-
vascular screening after PE is recommended; however, the how and when are yet to be determined. Given the large impact of a
previous preeclamptic pregnancy on cardiovascular risk, the question arises whether we should not intensify secondary preven-
tion in these high-risk women.
Summary Obstetric history can provide useful information about CVD risk in women after their reproductive life, especially if
they had a pregnancy complicated by preeclampsia. Early detection of hypertension could optimize prevention and treatment
strategies and mitigate CVD risk. For high-risk women, preeclampsia may be considered a first cardiovascular event that requires
secondary prevention according to guidelines.
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Introduction
Cardiovascular disease (CVD) is the leading cause of
death in women worldwide. In the last two decades, over-
whelming evidence has shown that CVD risk is elevated
after a pregnancy complicated by preeclampsia (PE)
[1–4]. Several global guidelines, such as the 2011
American College of Cardiology/American Heart
Association’s (ACC/AHA) guideline [5], the 2016
European Society of Cardiology (ESC) guideline CVD
prevention [6], and the 2017 ACC/AHA guideline on high
blood pressure [7], acknowledge preeclampsia as a
female-specific cardiovascular risk factor and recommend
timely risk monitoring after PE. As such, pregnancy acts
as a window for future cardiovascular health [8]. It is yet
to establish, however, whether preeclampsia is an inde-
pendent risk factor for CVD or acts through traditional
CVD risk factors [9]. The most common thought is that
PE is driven by an enhanced susceptibility for CVD and
interacts with environmental factors. This review aims to
describe the current knowledge on preeclampsia as a risk
factor for CVD later in life.
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Preeclampsia and Subsequent Cardiovascular
Risk
Preeclampsia is one of the hypertensive disorders of pregnan-
cy (HDP) and accounts for the most severe form. The
International Society for the Study of Hypertension (ISSHP)
defines preeclampsia as new-onset hypertension after
20 weeks gestation in combination with either proteinuria (≥
300 mg/day) or other maternal dysfunctions, such as renal
insufficiency, liver involvement, neurological or hematologi-
cal complications, or uteroplacental dysfunction [10].
Preeclampsia complicates 3–5% of all pregnancies, leading
to maternal and fetal morbidity caused by growth restriction
due to uteroplacental dysfunction.Moreover, it can potentially
lead to intrauterine death [11]. In Western countries, such as
the Netherlands, maternal mortality is low, but PE remains the
most important cause [12].
Hypertension is diagnosed when the systolic blood pres-
sure exceeds 140 mmHg or the diastolic blood pressure ex-
ceeds 90mmHg on two occasions [10, 13]. After a preeclamp-
tic pregnancy, women have at least a twofold increased risk of
developing any manifestation of CVD. The risk of developing
chronic hypertension is particularly elevated, with a four times
higher risk compared with women having had a normotensive
pregnancy [1, 2]. Furthermore, several meta-analyses showed
a 2.0 to 2.5 elevated risk of developing ischemic heart disease
[1, 3, 4]. In addition, the risk of future cerebrovascular disease
is twice higher [1, 3], and a fourfold increased risk was ob-
served for developing heart failure (HF) [4].
A retrospective cohort study in over 1.6 million pregnan-
cies demonstrated corresponding risks and showed that car-
diovascular complications of pregnancies, such as hyperten-
sive disorders of pregnancy, can identify women at young age
being at risk for premature CVD [14•]. In the 2.7 years fol-
lowing the pregnancy complicated by preeclampsia women
had a 2.5-fold increased risk for myocardial infarction (MI),
a 3.0-fold increased risk for HF, and a 2.3-fold increased risk
for stroke, compared with women after normotensive preg-
nancies [14•]. Women with chronic hypertension with
superimposed PE had the highest risk for MI, HF, and stroke.
Cardiovascular Risk Prediction
Common risk factors for both CVD and pregnancy complica-
tions such as preeclampsia include obesity, chronic hyperten-
sion, diabetes mellitus, renal disease, immune diseases, and
black race. Hypertension is the most important risk factor for
CVD, cerebrovascular disease, and chronic kidney disease.
Several studies recently showed that the inclusion of HDP
in any of the most frequently used CVD risk scores does not
improve the prediction of future CVD events [15•, 16, 17]. A
limitation of these studies however is that these risk prediction
models were tested in women aged 50 years or older, when
traditional CVD risk factors emerge as well. Stuart et al. ana-
lyzed data of women aged 40 years or older, showing that both
HDP and parity were independently associated with CVD at
ages 40 to 49 years [15•]. However, the addition of HDP to the
atherosclerotic cardiovascular disease (ASCVD) risk score
did not result in better risk stratification, as traditional cardio-
vascular risk factors and risk factors for preeclampsia, or HDP
in general, widely overlap. Since systolic blood pressure and
use of antihypertensive medication are important predictors in
these risk models, these factors may explain the lack of effect
of adding HDP to the models. Furthermore, women who have
hypertension after PE have a twofold increased risk of devel-
oping CVD, compared with women who are normotensive
after PE [18].
A discussion is currently evolving on whether we should
consider PE and severe HDP not as risk factors for CVD, but
as first manifestations of a cardiovascular event for which
secondary prevention rules are more appropriate. A recent
study showed that women after a pregnancy with PE have a
twofold higher risk of identifiable coronary artery calcium
(CAC) with CT scans at the age of 50 when compared with
a reference population [19••]. This means that signs of sub-
clinical atherosclerosis appear at a young age and many years
earlier than usual [20]. As hypertension is the first important
risk factor emerging after PE or severe HDP, a stricter blood
pressure control than current guidelines indicate in HDP-
affected patients may be the first important step forward for
this high-risk group. As hypertension determines up to half of
an individual’s CVD risk [21], 38% of cardiovascular mortal-
ity in women could be prevented by eliminating this risk fac-
tor [22]. Moreover, patients with a CVD event in history with-
out hypertension can benefit from antihypertensive treatment
to reduce MI, HF, and cerebrovascular disease [23].
Onset of Hypertension After Preeclampsia
Over the last years, several studies have been done to obtain
insight in the onset of hypertension and other CVD risk factors
after PE [24, 25]. Other CVD risk factors, such as lipid levels,
also show a less favorable profile after PE, but these are often
determined when women are still premenopausal and flattered
by their still high estrogen levels [26].
The timing to start screening for hypertension is still debat-
ed. Various studies showed that approximately 40% of women
with early-onset PE had hypertension 10 years after pregnan-
cy [24, 27]. This is in line with a more recent study by Heida
et al. [28] that showed a mean age of 43.5 years at onset of
chronic hypertension after HDP. A few studies [29–31]
showed the strongest risks for development of chronic hyper-
tension in the first 5 years after pregnancy. In one study, 41.5%
of women already had hypertension 1 year after severe PE, of
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which 17.5% had masked hypertension [32]. These findings
highlight the shortcomings of incidental in-office blood pres-
sure measurements and request other ways of measuring
blood pressure, such as ambulatory blood pressure monitoring
or home blood pressure monitoring.
As hypertension develops 10–15 years earlier in women
after PE compared with women after normotensive pregnan-
cies, screening from at least 35 years of age onwards is pro-
posed [26]. Prepregnancy risk factors, such as family history
of hypertension, obesity, and elevated blood pressure, are all
important in the onset of hypertension and other CVD risk
factors after pregnancy [33–35]. In a prospective cohort study,
however, Egeland et al. [36] showed that the increased risk of
hypertension persisted after adjustment for prepregnancy risk
factors.
Enhanced Inflammation After Previous
Preeclampsia
During PE, several markers of inflammation (cytokines) are
substantially increased in the maternal circulation and the pla-
centa, resulting in chronic systemic and local placental inflam-
mation, which contributes to the complications that occur dur-
ing PE. The most prominent markers are tumor necrosis factor
α (TNF-α), interleukin (IL) 6, and IL-17 [37]. TNF-α signal-
ing results in endothelial cell activation and a reduction in
nitric oxide synthase (NOS), leading to endothelial dysfunc-
tion that explains all maternal clinical features. The levels of
vasoconstrictor endothelin 1 (ET-1) are also increased. In con-
trast, the levels of IL-10, an anti-inflammatory marker that
inhibits the activation of interferon γ (IFN-γ), IL-2, and
TNF-α, are decreased in preeclamptic women [38]. This im-
balance between proinflammatory and regulatory cytokines
during a preeclamptic pregnancy suggests that PE is a state
of dysregulated immune activation.
Women with a history of PE have alterations in several mis-
cellaneousmarkers (TNF-α, IL-6, leptin, adiponectin, homocys-
teine, SE-selectin, and pregnancy-associated plasma protein-A
(PAPP-A)) at 8–10 years after the index pregnancy compared
with control subjects [39, 40]. Higher baseline levels of C-
reactive protein (CRP), IL-6, and fibrinogen have been observed
months to years after delivery in previously preeclamptic wom-
en [41]. An increase in the CRP response to vaccination and a
consistent pattern of increased acute-phase responses (APRs) to
vaccination for all inflammatory markers were also found
among women after PE compared with controls, indicating that
vascular responses have changed after PE [42]. This effect was
independent of the traditional cardiovascular risk factors, which
further enforces the concept that a preeclamptic pregnancy may
be considered a first vascular event. However, not all women
affected by PE seem to have an equally elevated CVD risk. It
remains to be elucidated whether women with an elevated
proinflammatory state after PE are at the highest risk of devel-
oping CVD in the years thereafter.
Signs of Subclinical Atherosclerosis After
Preeclampsia
Systemic inflammation accelerates endothelial dysfunction,
atherosclerosis, and premature arterial stiffness [43].
Therefore, the enhanced inflammatory state after a preeclamp-
tic pregnancy may induce hypertension and subclinical ath-
erosclerosis. Awidely used non-invasive measure to evaluate
subclinical atherosclerosis is carotid intima-media thickness
(cIMT) [44]. An increased cIMT value is a predictor of coro-
nary artery disease in both pre- and postmenopausal women
[45]. Two recent meta-analyses showed that cIMT values are
higher in women after preeclampsia compared with those in
women experiencing a normotensive pregnancy, both at time
of pregnancy and in the first 10 years postpartum [46, 47].
In a review on shared pathophysiological mechanisms, De
Jager and colleagues [48] showed that many common deter-
minants are involved in both PE and atherosclerotic plaque
erosions. Especially, IL-6 and TNF-α are major contributors
to the inflammatory response in these conditions.
The shared inflammatory response in PE and atherosclerot-
ic disease and the elevated cIMT values all suggest that for-
merly preeclamptic women have an increased risk of having
subclinical coronary atherosclerosis at a younger age.
In 2018, the first study was published that compared the
prevalence of coronary atherosclerosis using coronary artery
calcification (CAC) score in women aged 45 to 55 years
[19••]. Thirty percent of formerly preeclamptic women
showed signs of CAC around the age of 50 years compared
with 18% in the reference group [19••]. However, women
with a history of PE also had hypertension more often, which
may have contributed to the higher CAC scores. When having
an acute coronary syndrome (ACS), nearly all women with a
previous preeclampsia had chronic hypertension [49].
Preeclampsia Should Be Considered a First
Cardiovascular Event
Since CVD risk prediction models are not suitable to distin-
guish high-risk women after PE adequately, we have to iden-
tify better which women after PE are at highest risk. For those
with an enhanced inflammatory state and/or signs of subclin-
ical atherosclerosis, we should seriously consider to apply our
secondary prevention guidelines to prevent cardiovascular
disease. This implicates that we need a more stratified
follow-up program for women after a pregnancy with PE,
which may facilitate treatment decisions for elevated blood
pressure in a more timely manner than is currently done.
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The first step in the follow-up of these women is adequate
lifestyle advice and support provided by primary care physi-
cians and dieticians. In addition, exercise training may im-
prove physical condition [50]. Patient awareness of normal
levels of CVD risk factors, especially blood pressure levels,
is correlated with an increase in physical activity and improve-
ments in diet. However, most women do not know their num-
bers and are not aware of normal thresholds [51]. Patient em-
powerment in lifestyle management and knowledge on nor-
mal values of the traditional risk factors will improve their
awareness and motivation [52]. Self-measurement of blood
pressure using eHealth facilities may be helpful to detect ele-
vated blood pressure on time for adequate treatment.
Conclusion
Obstetric history can provide useful information about cardio-
vascular disease risk in women after their reproductive life,
especially if they had a pregnancy complicated by preeclamp-
sia. Evidence suggests that screening for cardiovascular risk
factors, such as hypertension, to prevent cardiovascular dis-
ease should start soon after pregnancy. Early detection of hy-
pertension could optimize prevention and treatment strategies
and mitigate CVD risk. For high-risk women, preeclampsia
may be considered a first cardiovascular event that requires
secondary prevention guidelines.
Future investigations should focus on optimal screening
methods for individual cardiovascular risk among women
with preeclamptic pregnancies.
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